Objective: To describe our surgical experience and clinical outcome in laparoscopic radical nephrectomy (LRN) for renal cell carcinoma (RCC) with level 1 renal vein tumor thrombus. Patients and Methods: 11 patients with RCC level 1 renal vein tumor thrombus were treated by LRN plus thrombectomy. The mean age was 66.8 years (SD ±11.313); the mean body mass index was 24.76 (SD ±5.091). In all cases, the surgical technique was defined by tumor characteristics and the surgeon's preferences. Results: Surgery was technically successful in all 11 patients. A hand-assisted approach was performed in 3 patients, while pure laparoscopy was used in 8. The mean surgical time was 108.3 min (SD ±28.284); the mean estimated blood loss was 108.33 ml (SD ±106.066); the average hospital stay was 2.8 days (SD ±0.707). There was 1 intraoperative complication (splenic laceration) that was managed laparoscopically. Pathologic examination confirmed RCC in all cases. There were no positive surgical margins. With a mean follow-up of 29 months (27-39), 2 patients had a recurrence. Conclusion: This report provides further evidence of the technical feasibility, safety and oncologic adequacy of the laparoscopic approach in RCC with level 1 renal vein involvement. A longer follow-up and multi-institutional studies are needed to adequately evaluate its potential oncologic benefit.

Keywords:
Laparoscopic radical nephrectomy, Renal tumor, Renal vein involvement
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2.
European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.3, 730 entity dictionary (2001). Lyon, 2001.
3.
SEER Program Public Use Data Tapes 1973-2002, November 2004 Submission. Bethesda, National Cancer Institute, Division of Cancer Control and Population Science, Surveillance Research Program, Cancer Statistics Branch, 2005.
4.
Jayson M, Sanders H: Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998;51:203-205.
5.
Luciani LG, Cestari R, Tallarigo C: Incidental renal cell carcinoma - age and stage characterization and clinical implications: study of 1,092 patients (1982-1997). Urology 2000;56:58-62.
6.
Blute ML, Leibovich BC, Lohse CM, et al: The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 2004;94:33-41.
7.
Sundaram CP, Rehman J, Landman J, et al: Hand assisted laparoscopic radical nephrectomy for renal cell carcinoma with inferior vena caval thrombus. J Urol 2002;168:176-179.
8.
Novara G, Ficarra V, Antonelli A, et al: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol 2010;58:588-595.
9.
Clayman RV, Kavoussi LR, Soper NJ, Dierks SM, Meretyk S, Darcy MD, Roemer FD, Pingleton ED, Thomson PG, Long SR: Laparoscopic nephrectomy: initial case report. J Urol 1991;146:278-282.
10.
Kapoor A, Nguan C, Al-Shaiji TF, et al: Laparoscopic management of advanced renal cell carcinoma with level I renal vein thrombus. Urology 2006;68:514-517.
11.
Ciancio G, Manoharan M, Katkoori D, et al: Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. Eur Urol 2010;57:667-672.
12.
McDougall EM, Clayman RV, Elashry OM, et al: Laparoscopic radical nephrectomy for renal tumor: the Washington University experience. J Urol 1996;155:1180-1185.
13.
Finelli A, Kaouk JH, Fergany AF, et al: Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int 2004;94:291-294.
14.
Savage SJ, Gill IS: Laparoscopic radical nephrectomy for renal cell carcinoma in a patient with level I renal vein tumor thrombus. J Urol 2000;163:1243-1244.
15.
Steinnerd LE, Vardi IY, Bhayani SB: Laparoscopic radical nephrectomy for renal carcinoma with known level I renal vein tumor thrombus. Urology 2007;69:662-665.
16.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 2004;240:205-213.
17.
Fergany AF, Gill IS, Schweizer DK, et al: Laparoscopic radical nephrectomy with level II vena caval thrombectomy: survival porcine study. J Urol 2002;168:2629-2631.
18.
Troxel S, Das S: Planned hand assisted laparoscopic left radical nephrectomy involving a level 1 renal vein tumor thrombus. J Urol 2002;168:1090-1091.
19.
Zisman A, Wieder JA, Pantuck AJ, et al: Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol 2003;169:909-916.
20.
Mickisch GH, Garin A, van Poppel H, et al: Radical nephrectomy plus interferon alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomised trial. Lancet 2001;358:966-970.
21.
Flanigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-1659.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.